Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05553938 · ClinicalTrials.gov registry record · Phase 1

Effects of Acute and Chronic Empagliflozin Heart Failure

A Phase 1 study of Heart Failure, sponsored by Yale University.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
2
Study locations

NCT05553938 is a Phase 1 study of Heart Failure that is actively recruiting participants, run by Yale University. The registered enrollment target is 60 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05553938, a Phase 1 study of Heart Failure, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a crossover of placebo patients to active therapy at 6 weeks-12 weeks.

Conditions Studied

Heart Failure

Interventions

  • DRUG Placebo
  • DRUG Empagliflozin 10 mg

Study Locations (2)

Connecticut

  • Yale New Haven Hospital - New Haven
  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-08-04
Est. Completion 2025-11
Phase Phase 1

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05553938

The ClinicalTrials.gov registry entry for NCT05553938 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05553938 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05553938 about?

NCT05553938 is a clinical study titled "Effects of Acute and Chronic Empagliflozin Heart Failure". This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a crossover of placeb...

What is the current status of trial NCT05553938?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-08-04. Estimated completion is 2025-11.

What conditions does trial NCT05553938 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT05553938?

The interventions under investigation include: Placebo (DRUG), Empagliflozin 10 mg (DRUG).

Who is sponsoring clinical trial NCT05553938?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05553938 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.